- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00838955
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Study Overview
Detailed Description
Temsirolimus 25 mg IV infusion will be given once weekly on days 1, 8, 15 and 22 of each cycle. Patients will be assessed for response with CT scans after the second cycle, and then after every other cycle until disease progression is confirmed.
Patients will be treated with Temsirolimus until disease progression, or up to six cycles. Continuation of therapy beyond cycles is at the discretion of the investigator.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed classical Hodgkin Lymphoma or Lymphocyte Predominant Hodgkin Lymphoma with progressive disease during or at the end of the previous therapy, as defined by the IWG criteria.
- Patient must have nodular sclerosing, lymphocyte depleted, or mixed cellularity Hodgkin Lymphoma (Classical Hodgkin Lymphoma), or Lymphocyte predominant Hodgkin Lymphoma.
- Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.
- Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging.
- A clearly defined, bidimensionally measurable lymph node or tumor mass measuring at least 2 cm in diameter on a CT scan.
- Patient should have had at least one line of prior chemotherapy. Patients relapsing after treatment with radiation therapy alone are not eligible.
- Age > than or equal to 18 years.
- Both men and women and members of all races and ethnic groups are eligible for this trial.
- Women must not be pregnant or breast-feeding due to lack of information about the safety of administration of Temsirolimus in pregnant and lactating patients. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.
- Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of pregnancy prevention.
- Patient must have a SWOG performance status between 0-2.
- Patient must have no prior treatment with an m-TOR inhibitor.
- Patient must not have active infections at the time of registration.
- Laboratory studies should be obtained within two weeks of study registration except where noted otherwise. Allowable laboratory values are listed below:
- Absolute neutrophil count > than or equal 1,000/mm3
- Hemoglobin > than or equal 8 gm/dL
- Platelets > than or equal 75,000/mm3
- Serum creatinine < than or equal to two times the upper limit of normal. Creatinine should be measured within seven days of registration.
- Total serum bilirubin < than or equal to ≤ 1.5 times the upper limit of normal. Total bilirubin should be measured within seven days of registration.
- AST (SGOT) < than or equal to 3 times the upper limit of normal.
- ALT (SGPT) < than or equal to 3 times the upper limit of normal.
- Fasting total cholesterol < than or equal to 350 mg/dL.
- Fasting triglyceride level < than or equal to 400 mg/dL.
- Patient must have a life expectancy of three months.
Exclusion Criteria:
- Patient must not have received prior allogeneic stem cell transplantation. Prior autologous stem cell transplantation more than six months prior to registration is acceptable.
- Patient must not have received prior chemotherapy, biologic therapy or radiation within three weeks prior to registration, and should have recovered from toxicities of prior therapy (to Grade 0 or 1).
- Patient must not have evidence of active CNS disease.
- Patient must not have an uncontrolled comorbid disease, including hyperlipidemia, hypertriglyceridemia, diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- Patient must not have a psychiatric illness or social situation that would limit compliance with study requirements.
- Patient must have a life expectancy of three months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Temsirolimus
Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
|
Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
Time Frame: 26 weeks
|
To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the toxicity of temsirolimus in this patient population.
Time Frame: 26 weeks
|
To evaluate the toxicity of temsirolimus in this patient population.
|
26 weeks
|
To estimate the time to progression after treatment with temsirolimus.
Time Frame: 5 years
|
To estimate the time to progression after treatment with temsirolimus.
|
5 years
|
To estimate overall survival after treatment with temsirolimus.
Time Frame: 5 years
|
To estimate overall survival after treatment with temsirolimus.
|
5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Danielle Shafer, DO, Loyola University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Hodgkin Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- 201170
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin's Lymphoma
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
-
Western Regional Medical CenterWithdrawnLymphoma | Hodgkin's Lymphoma | Non-hodgkin's LymphomaUnited States
-
West Virginia UniversityCompletedHodgkin's Lymphoma | Non-Hodgkin's LymphomaUnited States
Clinical Trials on Temsirolimus
-
Sheba Medical CenterStanley Medical Research InstituteUnknownSchizophrenia | Schizoaffective DisorderIsrael
-
St. Joseph's Healthcare HamiltonPfizer; McMaster UniversityCompletedRenal Cell CarcinomaCanada
-
AVEO Pharmaceuticals, Inc.Completed
-
Children's Hospital Medical Center, CincinnatiWithdrawnLymphoma, B-Cell | Leukemia, B-cellUnited States
-
Dana-Farber Cancer InstituteWyeth is now a wholly owned subsidiary of Pfizer; Millennium Pharmaceuticals...CompletedMultiple MyelomaUnited States
-
Mathias Witzens-HarigCharite University, Berlin, Germany; Ludwig-Maximilians - University of Munich and other collaboratorsUnknownDiffuse Large B-Cell LymphomaGermany
-
Georgetown UniversityWyeth is now a wholly owned subsidiary of PfizerCompletedAdvanced Solid TumorsUnited States
-
Goethe UniversityCompletedAcute Myeloblastic LeukemiaGermany
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed